Novavax (NVAX) Misses Q4 EPS by 1c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.00 --0%
EPS Growth %: -164.5%
Financial Fact:
Revenue: 102K
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -164.5%
Financial Fact:
Revenue: 102K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Note: EPS may not be comparable
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.98 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
